METHODS: In this retrospective, multicentric study the data of a total of 82 eyes with various causes of glaucoma that were treated with a single or multiple applications of SL-TSCPC were collected. Treatments were performed under general or local anesthesia with an 810 nm diode laser. Power was 2000 mW; duty cycle, 31.3%; total treatment duration, 80-320 s; equaling a total energy of 50-200 J per treatment session. Fifty-five eyes (55 patients) presented for all follow-ups, and these eyes were selected for further statistical analysis. The mean age was 60.0 ± 17.1 years, and 22 (40%) of the patients were female. Intraocular pressure (IOP) and dependence on further glaucoma medication were evaluated at 12 months following the initial treatment.
RESULTS: Eyes underwent 1 or 2 consecutive SL-TSCPC treatments. Median (min-max) baseline IOP of 34 (13-69) decreased to 21.5 (7-61), 22 (8-68), 20 (9-68), and 19.5 (3-60) mmHg at the 1, 3, 6, and 12-month postoperative timepoints respectively. The mean (± SD) IOP decrease at 12 months was 26 ± 27%, 39 ± 32%, and 49 ± 33% in the low (below 120 J, n = 18), medium (120-200 J, n = 24), and high (above 200 J, n = 13) cumulative energy groups respectively. At the 12-month timepoint, oral carbonic anhydrase use was discontinued in ¾ of the cases.
CONCLUSIONS: It was found that the repeated application of SL-TSCPC safely and efficiently decreases IOP in a Caucasian population with heterogenous causes of glaucoma, eyes with silicone oil responded to a greater extent. Inclusion of cumulative energy scales may contribute to better addressing repeated procedures in a standardized fashion.
方法:在本回顾性研究中,多中心研究收集了一次或多次应用SL-TSCPC治疗的82只眼的各种青光眼的数据。在全身麻醉或局部麻醉下用810nm二极管激光进行治疗。功率为2000mW;占空比,31.3%;总治疗持续时间,80-320秒;相当于每次治疗的总能量为50-200焦耳。55只眼睛(55名患者)进行所有随访,选择这些眼睛进行进一步的统计学分析。平均年龄为60.0±17.1岁,22例(40%)患者为女性。初始治疗后12个月评估眼压(IOP)和对进一步青光眼药物的依赖性。
结果:眼睛接受1或2次连续SL-TSCPC治疗。基线眼压中位数(最小-最大)34(13-69)降至21.5(7-61),22(8-68)20(9-68)术后1、3、6和12个月时间点分别为19.5(3-60)mmHg。12个月时平均(±SD)眼压下降26±27%,39±32%,低点为49±33%(低于120焦耳,n=18),中型(120-200J,n=24),和高(高于200J,n=13)个累积能量组。在12个月的时间点,在3个病例中,口服碳酸酐酶的使用已停止。
结论:发现重复应用SL-TSCPC可以安全有效地降低青光眼异质性高加索人群的IOP,眼睛用硅油反应的程度更大。包含累积能量标度可能有助于以标准化方式更好地解决重复程序。